Home/IPOs/CONCORDBIO
Start Date04-08-2023
Application Timing10am-5pm
Price Range₹705 - ₹741
Min Qty20
Min. Investment₹14100
Listing DateNA
Close Date08-08-2023
About Concord Biotech Limited
Concord Biotech is an India-based biopharma company and one of the leading global developers and manufacturers of select fermentation-based APIs across immunosuppressants and oncology in terms of market share based on volume. Concord Biotech commanded a market share of over 20% by volume in 2021 across identified fermentation?based API products with presence in all the key regions including the United States, Europe, and Japan (based on DMF filings).
Concord Biotech is among the few Indian immunosuppressant formulation manufacturers with US ANDA approvals to be integrated with in?house fermentation?based immunosuppressant APIs for select organ transplant drugs.
Global pharmaceutical spending grew from USD 1,070 billion (INR 74,678 billion) in 2018 to USD 1,287 billion (INR 95,672 billion) in 2021 at a CAGR of 6.4%. India's domestic healthcare market is growing rapidly and is projected to grow at a CAGR of 8% to 10% from 2022 to 2026.
India is a crucial supplier of generic drugs, supplying to address almost 40% of the total U.S. generic drug (formulation) demand and approximately 25% of the total drug demand in the UK. Given the increasing cost pressure imposed on healthcare systems and the drive to increase use of lower-cost generic drugs, the generic drugs segment has growth at a healthy pace and is expected to continue to do so.
Why To Invest in Concord Biotech Limited
Concord is a biopharma company, leading global developers and manufacturers of select fermentation-based APIs.
Strengths And Risks
+
Established presence across the complex fermentation value chain: : Over the last two decades since 2001, company has been able to build difficult-to-replicate technical expertise in the fermentation process.
+
Global leadership in immunosuppressant APIs: : They are one of the leading global developers and manufacturers of select fermentation-based APIs across immunosuppressants and oncology with a market share of over 20% by volume in 2021.
+
Manufacturing and R&D capabilities: : They have three manufacturing facilities in Gujarat. The facility in Dholka received the first inspection by USFDA in 2005, and the first inspection by the Government of Upper Bavaria, Germany for European Union Good Manufacturing Practice (EUGMP).
+
Diversified global customer base: : They have established long-standing relationships with key customers, including leading global generic pharmaceutical companies, They have over 200 customers in over 70 countries for both our API and formulation products.
+
Financial Performance: : For the financial years 2020, 2021 and 2022, our total revenue from operations was Rs. 5,123 million, Rs. 6,169.43 million and Rs. 7,129.33 million, respectively, representing a CAGR of 17.96% and EBITDA was Rs. 2,043 million, Rs. 3,271 million and Rs. 2,696.36 million, respectively.
-
Client Concentration: : They depend on a limited number of key customers for a substantial portion of revenues. Any significant reduction in demand from such customers may adversely affect business and results of operations.
-
High Competition: : The pharma industry is highly competitive. Inability to respond adequately to the competition may result in loss of market share.
-
Regulatory Risk: : They operate in highly regulated industry, any failure to obtain, maintain or renew licenses, permits and approvals can impact business and financial performance.
-
Pricing Pressure: : They face pricing pressure from their customers that can affect the ability to maintain or increase our product prices and impact profitability.
-
Government Incentives: : The company is currently entitled to govt’s PLI incentive schemes. Any decrease in or discontinuation in such schemes can affect their operations.
FAQs
What is the Concord Biotech Limited IPO? +
.When will the IPO open? +
.What is the lot size of the IPO? +
How to apply for an IPO? +
When will the IPO be allotted? +
When is the IPO listing date? +
Explore Other Products
